- Coordinator
- Weizmann Institute of Science, Israel
- Runs
- 1 July 2022 to 31 December 2023
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101069334
What the project is doing
In the project's own words, from its summary on CORDIS.
Ubiquitination is a post-translational modification (PTM) that is critical for numerous biological processes, including cell cycle, autoimmunity, immune responses, and cancer. This has instigated vast interest in targeting the ubiquitin machinery, and in elucidating ubiquitin-dependent events in pathologies. However, a key constraint is the lack of high-throughput methodologies for monitoring ubiquitination in clinical samples.
Current tools mostly provide a qualitative sense of ubiquitin substrates and are limited by the need for unique expertise and large amounts of biological material. To address this gap, we have established a PTM-profiling tool that utilizes enzymatic activity in biological samples (e.g. liquid biopsies), enabling readouts of several PTMs, across thousands of proteins, for multiple samples simultaneously. We will employ our platform technology to the discovery and development of ubiquitin-related diagnostics and therapeutic agents in the field of autoimmunity.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Weizmann Institute of Science | Rehovot | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI